Want to see TRAW full AI Analyst Report?
Traws Pharma (TRAW) Stock Statistics & Valuation Metrics
Total Valuation
Traws Pharma has a market cap or net worth of $4.55M. The enterprise value is $8.37M.
- Market Cap
- $4.55M
- Enterprise Value
- $8.37M
Share Statistics
Traws Pharma has 15,368,277 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 15,368,277
- Owned by Insiders
- 12.38%
- Owned by Institutions
- 36.97%
Financial Efficiency
Traws Pharma’s return on equity (ROE) is -14.58 and return on invested capital (ROIC) is 3379.02%.
- Return on Equity (ROE)
- -14.58
- Return on Assets (ROA)
- 0.86
- Return on Invested Capital (ROIC)
- 3379.02%
- Return on Capital Employed (ROCE)
- 33.79
- Revenue Per Employee
- 398.57K
- Profits Per Employee
- 1.31M
- Employee Count
- 7
- Asset Turnover
- 0.26
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Traws Pharma is -0.59. Traws Pharma’s PEG ratio is -0.01.
- PE Ratio
- -0.59
- PS Ratio
- 0.00
- PB Ratio
- -0.59
- Price to FCF
- -0.85
- Price to Operating Cash Flow
- -0.59
- PEG Ratio
- -0.01
Income Statement
In the last 12 months, Traws Pharma had revenue of 2.79M and earned 9.17M in profits. Earnings per share was 0.83.
- Revenue
- 2.79M
- Gross Profit
- 2.79M
- Operating Income
- -17.88M
- Pretax Income
- 9.17M
- Net Income
- 9.17M
- EBITDA
- -17.81M
- Earnings Per Share (EPS)
- 0.83
Cash Flow
In the last 12 months, operating cash flow was -5.33M and capital expenditures 0, giving a free cash flow of -5.33M billion.
- Operating Cash Flow
- -5.33M
- Free Cash Flow
- -5.33M
- Free Cash Flow per Share
- -0.50
Dividends & Yields
Traws Pharma pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -117.26%
- Earnings Yield
- -333.28%
Stock Price Statistics
- Beta
- 0.62
- 52-Week Price Change
- -88.79%
- 50-Day Moving Average
- 0.49
- 200-Day Moving Average
- 1.15
- Relative Strength Index (RSI)
- 26.35
- Average Volume (3m)
- 584.76K
Important Dates
Traws Pharma upcoming earnings date is Nov 12, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 14, 2026
- Next Earnings Date
- Nov 12, 2026
- Ex-Dividend Date
- ―
Financial Position
Traws Pharma as a current ratio of 0.72, with Debt / Equity ratio of 0.00%
- Current Ratio
- 0.72
- Quick Ratio
- 0.72
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.21
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Traws Pharma has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Traws Pharma EV to EBITDA ratio is -0.10, with an EV/FCF ratio of -0.27.
- EV to Sales
- 0.00
- EV to EBITDA
- -0.10
- EV to Free Cash Flow
- -0.27
- EV to Operating Cash Flow
- -0.27
Balance Sheet
Traws Pharma has $3.13M in cash and marketable securities with $0.00 in debt, giving a net cash position of $3.13M billion.
- Cash & Marketable Securities
- $3.13M
- Total Debt
- $0.00
- Net Cash
- $3.13M
- Net Cash Per Share
- $0.20
- Tangible Book Value Per Share
- -$0.73
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Traws Pharma is $1.00, which is 11.43% higher than the current price. The consensus rating is Neutral
- Price Target
- $1.00
- Price Target Upside
- 237.84% Upside
- Analyst Consensus
- Neutral
- Analyst Count
- 1
- Revenue Growth Forecast
- -100.00%
- EPS Growth Forecast
- 83.59%
Scores
- Smart Score
- ―
- AI Score
- 40
